Using a novel compact intraoperative imaging device, Synchronized Infra-Red Imaging System (SIRIS), and a targeted imaging agent, Tumor Paint BLZ-100, researchers aim to increase survival and reduce neurological deficits in patients with gliomas. In experimental models of brain, lung and breast tumors, SIRIS detects BLZ-100, which preferentially binds to a variety of human malignancies but shows little or no binding to normal human tissue. When stimulated by a laser in the near-infrared part of the spectrum, BLZ-100 emits a glow SIRIS captures.
Preliminary research shows SIRIS, along with BLZ-100, can delineate brain tumors in real time and assist surgeons in near-complete removal. Because SIRIS penetrates deep into tissue, BLZ-100 captures tumor metastasis.
The study Laser Fluorescence for Tissue Identification evaluates the investigational use of laser-induced fluorescence spectroscopy (LIFS) to detect brain tumors at the time of surgery. LIFS is a technique that utilizes a beam of light (laser) to differentiate tumor tissue from normal brain tissue.
During surgery, a low-intensity light beam will be focused on the surface of the brain. The fluorescence emitted from the brain tissue will then be analyzed by a computer in the operating room to locate tumor tissue.
- Principal Investigator: Chirag Patil, MD